Current Liabilities decreased faster than Tc Biopharm Holdings Plc's Cash & cash equivalent, this led to improvement in Tc Biopharm Holdings Plc's Quick Ratio to 0.29, Quick Ratio remained below Tc Biopharm holdings Plc average.

Within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Tc Biopharm Holdings Plc in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 0 to 2928.

Explain Quick Ratio?
How much Cash & cash equivalents TCBP�s has?
What are TCBP�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TCBP Quick Ratio	(Dec 31 2024) Q4	0 Q3	0 Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4
Y / Y Current Liabilities Change	-14.34 %	-	-54.74 %	-26.24 %	-34.89 %
Y / Y Cash & cash equivalent Change	500 %	-	-96.68 %	-76.68 %	-96.62 %
Quick Ratio MRQ	0.29	0.23	0.06	0.23	0.04
TCBP's Total Ranking	# 2928	# 0	# 0	# 2167	# 1961
Seq. Current Liabilities Change	-24.36 %	62.89 %	-38.63 %	13.28 %	-
Seq. Cash & cash equivalent Change	-1.45 %	508.84 %	-83.58 %	508.84 %	-

Quick Ratio fourth quarter 2024 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 813
Overall Market	# 2928

Quick Ratio Statistics
High	Average	Low
0.71	0.5	0.29
(Dec 31 2022)		(Mar 31 2024)

Financial Statements
Tc Biopharm Holdings Plc's Current Liabilities	$ 5 Millions	Visit TCBP's Balance sheet
Tc Biopharm Holdings Plc's Cash & cash equivalent	$ 2 Millions	Visit TCBP's Balance sheet
Source of TCBP's Sales		Visit TCBP's Sales by Geography

Cumulative Tc Biopharm Holdings Plc's Quick Ratio

TCBP's Quick Ratio for the trailling 12 Months

TCBP Quick Ratio	(Dec 31 2024) 12 Months	0 12 Months	0 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	-6.26 %	-14.05 %	-53.97 %	-60.4 %	-53.13 %
Y / Y Cash & cash equivalent TTM Growth	-66.49 %	-83.48 %	-92.77 %	-61.99 %	-30.46 %
Quick Ratio TTM	0.21	0.15	0.12	0.42	0.59
Total Ranking TTM	# 3748	# 0	# 0	# 3696	# 3337
Seq. Current Liabilities TTM Growth	-3.62 %	40.04 %	-22.92 %	-9.9 %	-11.63 %
Seq. Cash & cash equivalent TTM Growth	35.27 %	75.27 %	-78.25 %	-35 %	-33.31 %

Quick ratio ranking by company, industry and sector >> Back to TCBP Financial Strength Comparisons >> Go to Compare TCBP Quick Ratio to its Competitors

On the trailing twelve months basis TCBP Cash & cash equivalent more than doubled by 500 % in Q4 2024 year on year, while Current Liabilities faded to $5 millions, this led to increase in in Tc Biopharm Holdings Plc's Quick Ratio to 0.21, Quick Ratio remained below TCBP average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 151 other companies have achieved higher Quick Ratio than Tc Biopharm Holdings Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 0 to 3748.

Explain Quick Ratio?
How much Cash & cash equivalents TCBP�s has?
What are TCBP�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 152
Healthcare Sector	# 952
Within the Market	# 3748

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.71	0.53	0.29
(Dec 31 2022)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2024 MRQ Cash & cash equivalent	Dec 31 2024 MRQ Current Liabilities
Novavax inc	0.80	$ 923.118 Millions	$ 1,154.416 Millions
Protalix Biotherapeutics inc	0.77	$ 19.760 Millions	$ 25.621 Millions
Kalaris Therapeutics Inc	0.76	$ 1.639 Millions	$ 2.151 Millions
Mink Therapeutics Inc	0.66	$ 4.577 Millions	$ 6.960 Millions
Alpha Cognition Inc.	0.58	$ 2.808 Millions	$ 4.856 Millions
Amgen Inc	0.52	$ 11,973.000 Millions	$ 23,099.000 Millions
Alvotech	0.52	$ 51.428 Millions	$ 99.828 Millions
Coherus Oncology inc	0.45	$ 125.987 Millions	$ 282.981 Millions
Aim Immunotech Inc	0.43	$ 3.977 Millions	$ 9.296 Millions
Elutia Inc	0.40	$ 13.239 Millions	$ 33.395 Millions
Outlook Therapeutics Inc	0.35	$ 14.928 Millions	$ 42.503 Millions
Silexion Therapeutics Corp	0.35	$ 1.222 Millions	$ 3.523 Millions
Ladrx Corporation	0.34	$ 0.760 Millions	$ 2.259 Millions
Champions Oncology Inc	0.32	$ 2.618 Millions	$ 8.110 Millions
Atara Biotherapeutics Inc	0.32	$ 42.496 Millions	$ 134.574 Millions
Windtree Therapeutics Inc	0.31	$ 1.779 Millions	$ 5.717 Millions
Tc Biopharm holdings Plc	0.29	$ 1.500 Millions	$ 5.111 Millions
Vaxart Inc	0.29	$ 26.494 Millions	$ 90.878 Millions
Atlantic Coastal Acquisition Corp Ii	0.24	$ 2.916 Millions	$ 12.198 Millions
Xtant Medical Holdings Inc	0.22	$ 6.199 Millions	$ 27.809 Millions
Zeo Scientifix Inc	0.21	$ 0.720 Millions	$ 3.349 Millions
Bluebird Bio Inc	0.19	$ 62.305 Millions	$ 321.462 Millions
Armata Pharmaceuticals Inc	0.19	$ 9.291 Millions	$ 48.249 Millions
Agenus Inc	0.18	$ 40.437 Millions	$ 221.401 Millions
Tevogen Bio Holdings Inc	0.15	$ 1.283 Millions	$ 8.814 Millions
Aptose Biosciences Inc	0.12	$ 0.557 Millions	$ 4.459 Millions

Date modified: 2026-09-10T03:41:56+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.